Compare Neurocrine Biosciences Inc (NBIX) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Nano Dimension Ltd - ADR — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Nano Dimension Ltd - ADR trades at $1.55 (market cap $328.52M). The key difference: Neurocrine Biosciences Inc is far larger — about 43.7× Nano Dimension Ltd - ADR's market cap, and Neurocrine Biosciences Inc is more actively traded (1,237,180 versus 1,160,945). Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Nano Dimension Ltd - ADR for 43 Days on average.
| NBIX | NNDM | |
|---|---|---|
Market Cap | $14.36B | $328.52M |
Volume | 1,237,180 | 1,160,945 |
Sector | Health | Technology |
52-Week High | $185.50 | $2.14 |
52-Week Low | $123.10 | $1.21 |
Typical Hold Time | 23 Days | 43 Days |
Enterprise Value | $14.37B | -$76.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Nano Dimension (NNDM) trades at $1.56, up 0.65% with a bearish technical signal. The company shows revenue growth from $102M in 2025 to $121M in 2026 but remains unprofitable with a -135% net margin. Recent strategic actions include cost-cutting initiatives and board changes, with cash reserves of $758M providing operational runway despite negative cash flows.
The outlook remains challenging with persistent losses and negative cash flow, though valuation ratios appear attractive with P/S of 2.73 and P/B of 0.68. Key risks include execution of turnaround strategy and competitive pressures in the industrial 3D printing sector. Analyst sentiment is cautious given the company's ongoing restructuring efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
